MannKind Corp
MNKD4.996USD
+0.045+0.92%
Market hours （ET）Quotes delayed by 15 min
1.51BMarket Cap
54.86P/E TTM
More Details of MannKind Corp Company
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.
Company Info
Company codeMNKD
Company nameMannKind Corp
IPO dateJul 28, 2004
Founded at1991
CEODr. Michael E. Castagna, Pharm.D.
Number of employees407
Security typeOrdinary Share
Fiscal year-endJul 28
Address1 Casper Street
CityDANBURY
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code06810
Phone18186615000
Websitehttps://mannkindcorp.com/
Company codeMNKD
IPO dateJul 28, 2004
Founded at1991
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Lauren M. Sabella
Ms. Lauren M. Sabella
Executive Vice President - Operations
Executive Vice President - Operations
106.41K
-45.01%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
By RegionUSD
Name
Revenue
Proportion
United States
285.50M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
24.45%
Investment Advisor
16.58%
Hedge Fund
10.78%
Research Firm
3.38%
Individual Investor
1.63%
Pension Fund
0.35%
Bank and Trust
0.33%
Venture Capital
0.02%
Other
42.48%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
464
175.74M
57.84%
+7.73M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
2023Q1
412
147.80M
55.93%
-4.58M
2022Q4
408
144.92M
55.01%
+311.67K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
21.21M
6.98%
+360.93K
+1.73%
Dec 31, 2024
The Vanguard Group, Inc.
16.00M
5.26%
+420.33K
+2.70%
Dec 31, 2024
State Street Global Advisors (US)
9.95M
3.27%
+350.64K
+3.65%
Dec 31, 2024
Avoro Capital Advisors LLC
8.75M
2.88%
--
--
Dec 31, 2024
Nitorum Capital, L.P.
8.75M
2.88%
-410.19K
-4.48%
Dec 31, 2024
Geode Capital Management, L.L.C.
6.37M
2.1%
+35.35K
+0.56%
Dec 31, 2024
Two Sigma Investments, LP
6.27M
2.06%
+579.24K
+10.18%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.89M
1.61%
+3.59M
+275.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.48M
1.47%
+49.96K
+1.13%
Dec 31, 2024
D. E. Shaw & Co., L.P.
4.27M
1.41%
+798.47K
+23.01%
Dec 31, 2024
View more
Related ETFs
Update time: 6 hours ago
Update time: 6 hours ago
Name
Proportion
Invesco Biotechnology & Genome ETF
2.3%
ALPS Medical Breakthroughs ETF
1.18%
VictoryShares Small Cap Free Cash Flow ETF
0.61%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Federated Hermes MDT Small Cap Core ETF
0.42%
First Trust Small Cap Growth AlphaDEX Fund
0.41%
Global X Aging Population ETF
0.32%
iShares Micro-Cap ETF
0.29%
SPDR S&P Biotech ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.21%
View more
Invesco Biotechnology & Genome ETF
Proportion2.3%
ALPS Medical Breakthroughs ETF
Proportion1.18%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.61%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.44%
Federated Hermes MDT Small Cap Core ETF
Proportion0.42%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.41%
Global X Aging Population ETF
Proportion0.32%
iShares Micro-Cap ETF
Proportion0.29%
SPDR S&P Biotech ETF
Proportion0.28%
First Trust Small Cap Core Alphadex Fund
Proportion0.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data